9
Participants
Start Date
January 28, 2021
Primary Completion Date
November 9, 2022
Study Completion Date
November 9, 2022
Zoladex and Casodex
The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
Research Site, Beijing
Research Site, Shenyang
Research Site, Shanghai
Research Site, Hefei
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Changsha
Research Site, Changsha
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Chengdu
Research Site, Xi'an
Research Site, Ürümqi
Research Site, Shijiazhuang
Research Site, Zhengzhou
Lead Sponsor
AstraZeneca
INDUSTRY